AstraZeneca Pharma India Limited (BOM:506820)
India · Delayed Price · Currency is INR 8,499.70
+74.55 (0.88%)
At close: Jun 16, 2026
AstraZeneca Pharma India Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 22,756 | 17,163 | 12,955 | 10,030 | 8,056 | |
Revenue Growth (YoY) | 32.59% | 32.48% | 29.17% | 24.50% | -0.98% |
Cost of Revenue | 13,805 | 9,688 | 6,008 | 3,660 | 3,169 |
Gross Profit | 8,950 | 7,475 | 6,947 | 6,370 | 4,887 |
Selling, General & Admin | 3,804 | 2,590 | 2,419 | 2,591 | 2,303 |
Other Operating Expenses | 2,355 | 2,331 | 2,610 | 2,111 | 1,679 |
Operating Expenses | 6,616 | 5,327 | 5,233 | 4,881 | 4,193 |
Operating Income | 2,335 | 2,148 | 1,714 | 1,489 | 693.6 |
Interest Expense | -44.9 | -14.6 | -12 | -6.3 | -9.5 |
Interest & Investment Income | - | 315.6 | 325.7 | 231.2 | 114.8 |
Currency Exchange Gain (Loss) | - | -3.7 | -5 | 2.8 | -1.3 |
Other Non Operating Income (Expenses) | 284.9 | 87.5 | 20.2 | 2.1 | 4.6 |
EBT Excluding Unusual Items | 2,575 | 2,533 | 2,043 | 1,718 | 802.2 |
Merger & Restructuring Charges | -52.5 | - | - | -211.3 | - |
Gain (Loss) on Sale of Assets | - | 3.2 | 0.3 | 24.9 | 28.2 |
Asset Writedown | - | -4.6 | -12.4 | - | - |
Other Unusual Items | - | -967.9 | 164.3 | -191 | - |
Pretax Income | 2,522 | 1,564 | 2,195 | 1,341 | 830.4 |
Income Tax Expense | 646.8 | 406.2 | 580.3 | 348.1 | 214.4 |
Net Income | 1,875 | 1,157 | 1,615 | 992.9 | 616 |
Net Income to Common | 1,875 | 1,157 | 1,615 | 992.9 | 616 |
Net Income Growth | 62.02% | -28.34% | 62.67% | 61.19% | -33.98% |
Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 |
Shares Outstanding (Diluted) | 25 | 25 | 25 | 25 | 25 |
Shares Change (YoY) | -0.00% | - | - | - | - |
EPS (Basic) | 75.01 | 46.30 | 64.60 | 39.72 | 24.64 |
EPS (Diluted) | 75.01 | 46.30 | 64.60 | 39.72 | 24.64 |
EPS Growth | 62.02% | -28.34% | 62.67% | 61.19% | -33.98% |
Free Cash Flow | -167 | 636.1 | 171.1 | 497.7 | 911.8 |
Free Cash Flow Per Share | -6.68 | 25.44 | 6.84 | 19.91 | 36.47 |
Dividend Per Share | 36.000 | 32.000 | 24.000 | 16.000 | 10.000 |
Dividend Growth | 12.50% | 33.33% | 50.00% | 60.00% | 400.00% |
Gross Margin | 39.33% | 43.55% | 53.63% | 63.51% | 60.66% |
Operating Margin | 10.26% | 12.52% | 13.23% | 14.84% | 8.61% |
Profit Margin | 8.24% | 6.74% | 12.47% | 9.90% | 7.65% |
Free Cash Flow Margin | -0.73% | 3.71% | 1.32% | 4.96% | 11.32% |
EBITDA | 2,620 | 2,484 | 1,832 | 1,613 | 826.7 |
EBITDA Margin | 11.52% | 14.47% | 14.14% | 16.09% | 10.26% |
D&A For EBITDA | 285.8 | 336.3 | 117.2 | 124.7 | 133.1 |
EBIT | 2,335 | 2,148 | 1,714 | 1,489 | 693.6 |
EBIT Margin | 10.26% | 12.52% | 13.23% | 14.84% | 8.61% |
Effective Tax Rate | 25.65% | 25.98% | 26.43% | 25.96% | 25.82% |
Revenue as Reported | 23,041 | 17,569 | 13,303 | 10,291 | 8,204 |